We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Canadian Urological Association best practice report: Prostatespecific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer.
- Authors
Shaygan, Bobby; Zukotynski, Katherine; Bénard, François; Ménard, Cynthia; Kuk, Joda; Sistani, Golmehr; Bauman, Glenn; Veit-Haibach, Patrick; Metser, Ur
- Abstract
Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) is increasingly being used worldwide as part of the clinical workup for men with prostate cancer. With high overall accuracy for the detection of prostate cancer, PSMA-targeted PET has an increasingly established role in the setting of biochemical failure after primary therapy and an evolving role in the setting of initial disease staging; its utility for guiding management in the setting of metastatic disease is less clear. Although the specificity is high, familiarization with potential pitfalls in the interpretation of PSMA-targeted PET, including knowledge of the causes for falsepositive and negative examinations, is critical. The aim of this best practice report is to provide an illustrative discussion of the current and evolving clinical indications for PSMA-targeted PET, as well as a review of physiological radiopharmaceutical biodistribution and potential imaging pitfalls.
- Subjects
COMPUTED tomography; POSITRON emission tomography computed tomography; MAGNETIC resonance; PROSTATE cancer; CLINICAL indications
- Publication
Canadian Urological Association Journal, 2021, Vol 15, Issue 6, p162
- ISSN
1911-6470
- Publication type
Article
- DOI
10.5489/cuaj.7268